Mallebrin (Aluminium Chloride Hexahydrate)

The compound precipitates proteins on the surface of skin or mucous membranes, creating a thin film that contracts tissue, reduces glandular secretions, and provides a mild antiseptic environment. This astringent action helps control moisture, limit irritation, and promote hemostasis.

The appropriate dose and frequency of Mallebrin are determined by the prescribing healthcare professional based on the specific indication, severity of the condition, and patient factors. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Safety data for aluminium chloride hexahydrate in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Mallebrin.

To request Mallebrin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Mallebrin’s active ingredient, aluminium chloride hexahydrate, offers a strong protein‑precipitating effect that is comparable to other aluminium‑based astringents but may provide a longer duration of action on mucosal surfaces. Compared with zinc chloride or tannic acid preparations, it often produces a more pronounced reduction in secretions, though the choice depends on the clinical scenario and tolerance.

Mallebrin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed when not in use and avoid exposing the product to extreme temperatures or humidity.

Mallebrin is applied topically to the affected skin or mucosal area. The prescriber will advise the appropriate amount, method of application (e.g., swab, drop, or thin film), and frequency. The product is not intended for systemic ingestion.

Serious adverse reactions, although rare, include allergic contact dermatitis, severe skin ulceration, systemic aluminium toxicity, and anaphylaxis. Patients should seek immediate medical attention if they experience widespread rash, swelling, difficulty breathing, or persistent ulceration.

Mallebrin should be avoided in individuals with known hypersensitivity to aluminium salts, those with extensive broken mucosa at the intended site of application, and patients with severe renal impairment unless directed by a physician. Pregnant or breastfeeding women should only use it after consulting their healthcare provider.